Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer

Related Experiment Video

Updated: May 20, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Paolo Fagone1, Marco Donia, Katia Mangano

  • 1Department of Bio-Medical Sciences, School of Medicine, University of Catania, 95124 Catania, Italy.

Basic & Clinical Pharmacology & Toxicology
|July 6, 2012
PubMed

Insights

Rapamycin and temsirolimus show similar effectiveness in inhibiting prostate cancer cell growth. Both drugs target the mammalian target of rapamycin (mTOR) pathway, crucial for cell proliferation.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Rapamycin is a macrocyclic lactone used in cancer treatment and transplant rejection prevention.
  • It functions by inhibiting the mammalian target of rapamycin (mTOR).
  • The phosphoinositide 3-kinase (PI3K)/AKT pathway is frequently activated in advanced prostate cancer, suggesting mTOR inhibitors as a therapeutic strategy.

Purpose of the Study:

  • To compare the anti-proliferative effects of rapamycin and temsirolimus on prostate cancer cell lines.
  • To evaluate their efficacy both in vitro and in vivo.

Main Methods:

  • Comparative study design.
  • Utilized prostate cancer cell lines (LnCap and PC3).
  • Assessed in vitro and in vivo growth inhibition.

Main Results:

  • Rapamycin and temsirolimus demonstrated comparable anti-proliferative effects.
  • Both drugs were effective against prostate cancer cells in vitro and in vivo.

Conclusions:

  • Rapamycin and temsirolimus exhibit similar efficacy in combating prostate cancer growth.
  • These findings support the potential of mTOR inhibitors in prostate cancer therapy.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...